Phathom Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Phathom Pharmaceuticals
PHAT Stock  USD 5.54  0.70  14.46%   
Phathom Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Phathom Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Phathom Pharmaceuticals financial statements helps investors assess Phathom Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Phathom Pharmaceuticals' valuation are summarized below:
Gross Profit
47.3 M
Market Capitalization
337 M
Enterprise Value Revenue
4.3743
Revenue
55.3 M
Earnings Share
(5.29)
There are currently one hundred twenty trending fundamental ratios for Phathom Pharmaceuticals that can be evaluated and compared over time across competitors. All traders should check out Phathom Pharmaceuticals' recent fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 665.2 M in 2025, whereas Enterprise Value is likely to drop slightly above 205.4 M in 2025.

Phathom Pharmaceuticals Total Revenue

58.01 Million

Check Phathom Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phathom Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 15.9 M, Depreciation And Amortization of 834.8 K or Interest Expense of 75.6 M, as well as many indicators such as Price To Sales Ratio of 8.82, Dividend Yield of 0.0 or Days Sales Outstanding of 243. Phathom financial statements analysis is a perfect complement when working with Phathom Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Phathom Pharmaceuticals Correlation against competitors.
For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.

Phathom Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets267.1 M378.3 M123.4 M
Slightly volatile
Short and Long Term Debt Total475.9 K501 K26.2 M
Slightly volatile
Other Current Liabilities77.9 M74.2 M14.8 M
Slightly volatile
Total Current Liabilities90 M85.7 M21.2 M
Slightly volatile
Accounts Payable8.8 M10.5 M4.1 M
Slightly volatile
Cash243.5 M297.3 M112.5 M
Slightly volatile
Cash And Short Term Investments243.5 M297.3 M112.5 M
Slightly volatile
Common Stock Shares Outstanding40.4 M63.2 M22.9 M
Slightly volatile
Liabilities And Stockholders Equity267.1 M378.3 M123.4 M
Slightly volatile
Capital Surpluse458.1 M691.8 M251.2 M
Slightly volatile
Other Current Assets11.1 M20.9 M5.1 M
Slightly volatile
Other Stockholder Equity657.4 M1 B302.5 M
Slightly volatile
Total Liabilities663.5 M631.9 M143 M
Slightly volatile
Short and Long Term Debt5.1 M8.5 M4.2 M
Slightly volatile
Total Current Assets259.7 M360.1 M120 M
Slightly volatile
Short Term Debt1.7 M1 M2 M
Very volatile
Other Liabilities5.8 M8.6 M3.9 M
Slightly volatile
Property Plant And Equipment Net3 M2.1 M2 M
Slightly volatile
Other Assets816.6 K723.6 K503.5 K
Slightly volatile
Long Term Debt107.5 M201.4 M56.2 M
Slightly volatile
Common Stock Total Equity2.9 K3.5 K2.4 K
Slightly volatile
Long Term Debt Total55.8 M103.1 M43.5 M
Slightly volatile
Capital Lease Obligations475.9 K501 K977 K
Pretty Stable
Property Plant And Equipment Gross4.2 M4.9 M2.5 M
Slightly volatile
Non Current Liabilities Other362 M344.8 M72.9 M
Slightly volatile
Common Stock4 K6 K2.8 K
Slightly volatile
Property Plant Equipment2.4 M4 M2 M
Slightly volatile

Phathom Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense75.6 M72 M14.5 M
Slightly volatile
Selling General Administrative305.2 M290.7 M57.7 M
Slightly volatile
Other Operating Expenses349.4 M332.7 M87.5 M
Slightly volatile
Research Development48.6 M34.1 M29.6 M
Slightly volatile
Total Operating Expenses341 M324.7 M86.5 M
Slightly volatile
Cost Of Revenue8.4 M8 M1.1 M
Slightly volatile
Reconciled Depreciation521 K795 K214.7 K
Slightly volatile

Phathom Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.7 M1.7 M12.6 M
Very volatile
Net Borrowings61.2 M109.8 M35 M
Slightly volatile
Other Cashflows From Financing Activities1.5 M1.6 M32.3 M
Slightly volatile
Depreciation447.9 K795 K210.1 K
Slightly volatile
Other Non Cash Items26.8 M42.7 M16.3 M
Slightly volatile
Capital Expenditures128.2 K135 K1.9 M
Pretty Stable
Total Cash From Financing Activities178.5 M182.8 M83.1 M
Slightly volatile
End Period Cash Flow244.5 M300.1 M112.9 M
Slightly volatile
Change To Netincome47.3 M38.7 M26.6 M
Slightly volatile
Stock Based Compensation21.3 M24 M8.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.829.2846602
Slightly volatile
Days Sales Outstanding243256798
Slightly volatile
Stock Based Compensation To Revenue0.410.435257.8195
Slightly volatile
Capex To Depreciation3.13.272 K
Slightly volatile
EV To Sales3.723.9135290
Slightly volatile
Payables Turnover0.80.75880.1167
Slightly volatile
Research And Ddevelopement To Revenue0.590.616864.0954
Slightly volatile
Capex To Revenue1.922.162.3514
Slightly volatile
Cash Per Share4.544.70532.8149
Slightly volatile
Days Payables Outstanding45748123.6 K
Slightly volatile
Income Quality0.540.79790.7266
Pretty Stable
Current Ratio3.994.20096.9731
Pretty Stable
Receivables Turnover0.741.42410.4998
Slightly volatile
Capex Per Share0.03480.03660.6488
Slightly volatile
Revenue Per Share0.920.87460.1238
Slightly volatile
Interest Debt Per Share1.541.14771.0527
Slightly volatile
Debt To Assets0.00130.00131.3203
Slightly volatile
Days Of Payables Outstanding45748123.6 K
Slightly volatile
Ebt Per Ebit1.431.20491.184
Slightly volatile
Long Term Debt To Capitalization1.221.910.7211
Slightly volatile
Quick Ratio3.964.16356.967
Pretty Stable
Net Income Per E B T0.81.020.8974
Slightly volatile
Cash Ratio3.293.46756.627
Pretty Stable
Days Of Sales Outstanding243256798
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.261.161.4608
Slightly volatile
Fixed Asset Turnover27.7726.4493.5535
Slightly volatile
Debt Ratio0.00130.00131.3203
Slightly volatile
Price Sales Ratio8.829.2846602
Slightly volatile
Asset Turnover0.150.1460.0199
Slightly volatile
Gross Profit Margin0.650.85570.7548
Very volatile

Phathom Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap665.2 M513 M411.6 M
Slightly volatile
Enterprise Value205.4 M216.2 M311.8 M
Slightly volatile

Phathom Fundamental Market Drivers

Cash And Short Term Investments297.3 M

Phathom Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Phathom Pharmaceuticals Financial Statements

Phathom Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Phathom Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Phathom Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Phathom Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue21.1 M22.1 M
Total Revenue55.3 M58 M
Cost Of Revenue8 M8.4 M
Stock Based Compensation To Revenue 0.44  0.41 
Research And Ddevelopement To Revenue 0.62  0.59 
Capex To Revenue 2.16  1.92 
Revenue Per Share 0.87  0.92 
Ebit Per Revenue(5.02)(5.27)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY